Introduction {#sec1_1}
============

Combined central retinal artery occlusion (CRAO) and central retinal vein occlusion (CRVO) is an uncommon retinal vascular disease causing sudden visual acuity loss. This is rare in young adults, and vasculitis and thromboembolic disorders are the main etiologies in these patients \[[@B1]\]. Factor V Leiden (FVL) mutation is a common mutation that results in a mild prohemostatic state and is a risk factor for retinal vein occlusions \[[@B2]\]. However, combined CRAO and CRVO in patients with FVL mutation is very rare (only 3 cases published) \[[@B1],[@B3]\]. The prognosis of combined CRAO and CRVO is very poor, and the affected eyes typically develop severe complications, such as rubeosis iridis and neovascular glaucoma \[[@B4]\].

We report a rare case of combined CRAO and CRVO in a patient with FVL mutation. This is the first case of combined CRAO and CRVO treated with hyperbaric oxygen therapy (HBOT).

Case Presentation {#sec1_2}
=================

A 49-year-old female presented to the emergency department with sudden vision loss in the left eye (LE) with onset 5 h before. The patient also reported 2 episodes of sudden blurring of vision in her LE (10 and 8 days before) that lasted about 15 min and then fully recovered. Best corrected visual acuity (BCVA) was 10/10 in the right eye (RE) and 1/20 in the LE. An anterior segment examination revealed a left relative afferent pupillary defect. A left fundus examination revealed few intraretinal hemorrhages, mildly dilated and tortuous retinal veins, narrowed retinal arteries and a mildly cream-colored edematous appearance of the retinal posterior pole. The RE examination was normal. The past medical history included anxiety, venous peripheral insufficiency, 2 spontaneous abortions and 1 episode of deep venous thrombosis of the leg 12 years before. Her usual medication was zolpidem 10 mg once a day.

Fluorescein angiography (FA) of the LE (fig. [1a-e](#F1){ref-type="fig"}) showed a delay of dye emergence in retinal arteries (19 s after injection) and a prolonged arteriovenous transit time with laminar flow in the retinal veins only 55 s after the injection. Also, venous network filling was delayed and was not completed 79 s after the injection (fig. [1e](#F1){ref-type="fig"}). No embolic material was seen. Optical coherence tomography (OCT) showed an increase in thickness and hyperreflectivity of the inner retinal layers with hyporeflectivity of the outer retinal layers (fig. [1f](#F1){ref-type="fig"}). This clinical picture was consistent with the diagnosis of combined CRAO and CRVO.

Initial treatment consisted of urgent HBOT, which begun 3 h after presentation with 100% oxygen at a pressure of 2.4 ATA for 90 min and acetylsalicylic acid at 150 mg/day. Another HBOT session was done 7 h after the first session. There was marked improvement in vision after these HBOT sessions, with BCVA of 5/10.

The laboratory data only showed hyperlipidemia. An autoantibody screening was negative and inflammatory markers were normal. Echocardiography, neck vessel Doppler ultrasound and brain magnetic resonance imaging results were normal. The patient was sent to a hematology consult to complete thrombophilia screening.

The patient completed a total of 9 sessions of HBOT in 7 days (2 sessions on days 1 and 2 and then 1 daily session until stabilization of visual acuity). BCVA improved to 10/10 with significant improvement in FA (fig. [2a-c](#F2){ref-type="fig"}).

Forty-five days later, she developed a new LE CRVO, and BCVA decreased to 5/10 (fig. [2d, e](#F2){ref-type="fig"}). At that time, she started oral anticoagulation with acenocoumarol because an underlying hypercoagulable state was suspected. After 2 weeks, the thrombophilia screening results were available and revealed an abnormal resistance to activated protein C (1.21; normal value: \>2.14), and a genetic study showed homozygosity for FVL mutation. After 2 months, BCVA decreased to \<1/20 because of significant macular edema (fig. [2f](#F2){ref-type="fig"}), and the patient was submitted to 3 monthly injections of 1.25 mg bevacizumab.

At present (after 10 months), the patient is in a stable condition with BCVA of 6/10; the hemorrhages were absorbed, the dilatation and tortuosity of the retinal veins had subsided (fig. [3a, b](#F3){ref-type="fig"}), and OCT showed no macular edema (fig. [3c](#F3){ref-type="fig"}). Humphrey 24-2 visual field testing showed nasal and paracentral scotoma (fig. [3d](#F3){ref-type="fig"}). Oral anticoagulation will become a life-long treatment in this patient in order to prevent recurrences.

Discussion {#sec1_3}
==========

We reported a rare case of combined CRAO and CRVO in a patient with FVL mutation. The diagnostic criteria for this disease are acute unilateral visual loss with ischemic whitening of the retinal posterior pole, with or without a cherry-red spot on the macula, retinal hemorrhages, enlarged and tortuous retinal veins in 4 quadrants, delayed arterial dye filling and prolonged arteriovenous transit time on FA \[[@B3],[@B5]\]. Our case met all these criteria and showed simultaneous signs of CRAO (mildly edematous retinal posterior pole displaying a cream-colored appearance and prolonged retinal arterial transit time in FA) and mild signs of CRVO (a few intraretinal hemorrhages, mildly dilated and tortuous retinal veins and delayed venous network filling in FA). The patient was considered to have developed incomplete CRAO with mild CRVO, followed by complete CRVO after 45 days.

Iijima and Tsumura \[[@B6]\] described similar cases. A possible common mechanism in those cases may be that intravenous thrombus formation is accelerated by the decreased blood flow induced by incomplete CRAO, and that the abrupt increase in retinal arterial blood flow results in increased intravenous pressure followed by augmented hemorrhages and venous dilation \[[@B6]\]. However, in our case the increase in retinal hemorrhages and venous dilation only occurred 45 days later, which is why we think this was a new episode of CRVO and not an exacerbation of the previous one. Nevertheless, this mechanism may explain why a slight increase in retinal hemorrhages was observed 24 h after initiating HBOT.

This is only the 4th reported case of combined CRVO and CRAO associated with FVL mutation \[[@B1],[@B3]\]. Due to the high frequency of severe visual impairment in this disease, the rapid onset of severe complications and the lack of an alternative therapy, an effective emergency treatment capable of reversing the visual loss is urgently needed. HBOT has been used during the past decades to treat patients with CRAO, and 65% of all treated cases have shown improvement \[[@B7]\]. This is the first described case of combined CRAO and CRVO treated with HBOT. The rationale behind this treatment is that if supplemental oxygen is provided, oxygen from the choroidal circulation may diffuse in adequate quantity to the retinal inner layers to maintain retinal function and restore vision. We believe that our patient had developed combined CRAO and CRVO that was mild and that allowed significant recovery of function with the help of the supplemental oxygen provided by HBOT, which maintains retinal viability until obstructed retinal arteries recanalize.

In conclusion, combined CRVO and CRAO in young adults should be investigated thoroughly for embolic sources, thrombophilic disorders as well as local ocular conditions. Timely diagnosis and rapid intervention may help to significantly restore visual function and prevent complications. Our case was treated with HBOT, and the visual result was very good.
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![Initial features. **a** Fundus photograph showing moderate dilatation and a tortuous venous network (arrow), few intraretinal hemorrhages (arrowheads) and ischemic whitening of the retinal posterior pole. **b**, **c** Retinal arterial phase angiograms. Retinal arterial filling is delayed and is not completed 20 s after emergence of the dye in the retinal arteries at the optic disk (**c**, arrow). This finding indicates severe impairment of the retinal arterial supply. **d**, **e** Retinal arteriovenous phase angiogram. The arteriovenous transit time, from emergence of the dye in the retinal arteries to the appearance of venous laminar flow at the optic disk, is prolonged to 36 s (normal: ≤2 s). There is no capillary occlusion at the posterior pole. Venous network filling is delayed and is not completed 24 s (normal: ≤15 s) after the appearance of venous laminar flow (**e**, arrows). **f** OCT image showing hyperreflectivity of the inner retinal layers and hyporeflectivity of the outer retinal layers.](cop-0006-0462-g01){#F1}

![**a-c** After HBOT. **a** Fundus photograph obtained 24 h after initiating the therapy, showing a slight increase in retinal hemorrhages. **b**, **c** Fluorescein angiograms of the fundus obtained at day 8 (after completing HBOT). **b** Retinal arteriovenous phase. Retinal arterial filling is beginning shortly after choroidal filling and is rapidly completed; 13 s after dye injection, we already observe the early appearance of venous laminar flow. The arteriovenous transit time has returned to normal at 2 s. **c** Retinal venous phase. Venous network filling has greatly improved but is still slightly prolonged (18 s; normal: \<15 s). **d-f** New CRVO 45 days later. **d** Fundus photograph showing 1 peripapillary cotton-wool spot, intraretinal hemorrhages and tortuous and dilated retinal veins. **e** Fluorescein angiogram at 28 s showing an increased transit time of fluorescein flow from the arterial to the lamellar venous phase with delayed venous filling. **f** OCT 2 months after the new CRVO, showing significant macular edema with a central foveal thickness of 585 µm.](cop-0006-0462-g02){#F2}

![After 10 months. **a**, **b** Fundus (**a**) and red-free (**b**) photographs showing mild arterial retinal narrowing without intraretinal hemorrhages or macular edema. **c** OCT showing absence of macular edema. **d** Humphrey 24-2 visual field test (SITA standard strategy) numerical sensitivity plot and pattern deviation plot showing nasal and paracentral scotoma caused by retinal ischemia.](cop-0006-0462-g03){#F3}

[^1]: This case was presented in an oral communication at the 'Reunião dos Grupos Portugueses de Retina e Vítreo e de Órbita e Oculoplástica\', Figueira da Foz (Portugal), October 16-17, 2015.
